25 filings
8-K
CNTX
Context Therapeutics Inc
2 May 24
Context Therapeutics Announces $100 Million Private Placement
7:37am
8-K
CNTX
Context Therapeutics Inc
1 Apr 24
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
7:32am
8-K
CNTX
Context Therapeutics Inc
21 Mar 24
Amendments to Articles of Incorporation or Bylaws
7:31am
8-K
CNTX
Context Therapeutics Inc
6 Mar 24
March 2024 Corporate Presentation Advancing Medicines for Solid Tumors
7:30am
8-K
CNTX
Context Therapeutics Inc
31 Oct 23
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
9:04am
8-K
h1kp7b2f
7 Aug 23
August 2023 Corporate Presentation Advancing Medicines for Solid Tumors
8:11am
8-K
qs59pl cj
20 Jun 23
Other Events
8:35am
8-K
y3kgbl1
2 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
j2i1su1ri29ax6rkwd
22 Mar 23
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
5:09pm
8-K
8m0fk22km9kl
6 Feb 23
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
7:31am
8-K
iswesjym3 mdi19e9h1o
27 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:02pm
8-K
mohtucz2vw
4 Jan 23
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
7:31am
8-K
nux 2k508h5
8 Dec 22
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
7:32am
8-K
xmq ncjomdm6
1 Dec 22
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
8:01am
8-K
kbwmf3
9 Nov 22
November 2022 Corporate Presentation Advancing Medicines for Female Cancers
4:13pm
8-K
xqhv2fm0 dwl2stcrs8c
27 Sep 22
Regulation FD Disclosure
7:37am
8-K
qmolz65dw 85af7j
2 Aug 22
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
7:31am
8-K
5p72kj3 lb6
3 Jun 22
Submission of Matters to a Vote of Security Holders
4:03pm
8-K
5h10ngv2 5ryx
23 Mar 22
Context Therapeutics® Reports Full Year 2021 Operating and Financial Results
4:06pm
8-K
0sp0e 34kzx55
10 Jan 22
Corporate Presentation January 2022 BRINGING CHANGE FOR FEMALE CANCERS
8:01am